Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)

Spyre Therapeutics (SYRE) posted Long-Term Deferred Tax of $566000.0 for Q4 2022.

Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022) Analysis & Trends

Spyre Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $566000.0 for Q4 2022.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $566000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $566000.0 (changed N/A YoY) and the FY2022 annual result came in at $566000.0, changed N/A from the prior year.
Long-Term Deferred Tax was $566000.0 for Q4 2022 at Spyre Therapeutics.
Across five years, Long-Term Deferred Tax topped out at $566000.0 in Q4 2022 and bottomed at $566000.0 in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Spyre Therapeutics	257.83 Mn	257.83 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	566,000.00